Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Serous Carcinoma
Research from University of Toronto provide new insights into serous carcinoma
October 9th, 2008
"To update the data on the expression of 'mesothelioma markers' by serous carcinomas of various sites we have studied cases from ovary (n = 56), endometrium (n = 37), fallopian tube (n = 6), primary peritoneum (n = 5) and cervix (n = 3) using a panel of antibodies (WT1, P53, estrogen receptors, HER2/neu, D2-40, cytokeratin 5/6 and E-cadherin). Ovarian carcinomas demonstrated D2-40 and cytokeratin 5/6 immunoreactivity in 23.2 and 55.4% of cases, respectively," scientists in Toronto, Canada report. "Endometrial carcinomas demonstrated D2-40 and cytokeratin 5/6 immunoreactivity in 43.2 and 37.8% of cases, respectively. D2-40 staining pattern was predominantly focal;...
Source: Women's Health Weekly (2008-10-09)
|
